A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

NCT05736107 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Subcutaneous Fat

Interventions

DRUG: CBL-514 Injection
OTHER: 0.9% Sodium Chloride

Sponsor

Caliway Biopharmaceuticals Co., Ltd.